These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


161 related items for PubMed ID: 16806263

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway.
    Irukayama-Tomobe Y, Miyauchi T, Sakai S, Kasuya Y, Ogata T, Takanashi M, Iemitsu M, Sudo T, Goto K, Yamaguchi I.
    Circulation; 2004 Feb 24; 109(7):904-10. PubMed ID: 14967736
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats.
    Jozefowicz E, Brisson H, Rozenberg S, Mebazaa A, Gelé P, Callebert J, Lebuffe G, Vallet B, Bordet R, Tavernier B.
    Crit Care Med; 2007 Mar 24; 35(3):856-63. PubMed ID: 17255874
    [Abstract] [Full Text] [Related]

  • 6. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation.
    Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y.
    Life Sci; 2008 Apr 09; 82(15-16):884-91. PubMed ID: 18346759
    [Abstract] [Full Text] [Related]

  • 7. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.
    Labinskyy V, Bellomo M, Chandler MP, Young ME, Lionetti V, Qanud K, Bigazzi F, Sampietro T, Stanley WC, Recchia FA.
    J Pharmacol Exp Ther; 2007 Apr 09; 321(1):165-71. PubMed ID: 17215446
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells.
    Dragomir E, Tircol M, Manduteanu I, Voinea M, Simionescu M.
    Vascul Pharmacol; 2006 Jun 09; 44(6):440-9. PubMed ID: 16600694
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure.
    Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S, Nattel S.
    Cardiovasc Res; 2007 Apr 01; 74(1):75-84. PubMed ID: 17270161
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway.
    Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Noda A, Izawa H, Nagata K, Yokota M.
    Clin Exp Pharmacol Physiol; 2006 Dec 01; 33(12):1164-71. PubMed ID: 17184496
    [Abstract] [Full Text] [Related]

  • 20. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure.
    Ichihara S, Noda A, Nagata K, Obata K, Xu J, Ichihara G, Oikawa S, Kawanishi S, Yamada Y, Yokota M.
    Cardiovasc Res; 2006 Feb 15; 69(3):726-35. PubMed ID: 16165109
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.